KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Novartis Ag (NVS) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to 436.71%.

  • Novartis Ag's EBITDA Margin rose 4098800.0% to 436.71% in Q4 2025 from the same period last year, while for Dec 2025 it was 536.94%, marking a year-over-year increase of 5080400.0%. This contributed to the annual value of 32.36% for FY2025, which is 34500.0% up from last year.
  • According to the latest figures from Q4 2025, Novartis Ag's EBITDA Margin is 436.71%, which was up 4098800.0% from 616.58% recorded in Q3 2025.
  • Novartis Ag's 5-year EBITDA Margin high stood at 709.74% for Q1 2025, and its period low was 14.96% during Q3 2023.
  • For the 5-year period, Novartis Ag's EBITDA Margin averaged around 129.2%, with its median value being 24.68% (2021).
  • As far as peak fluctuations go, Novartis Ag's EBITDA Margin crashed by -94200bps in 2022, and later soared by 6812300bps in 2025.
  • Quarter analysis of 5 years shows Novartis Ag's EBITDA Margin stood at 19.37% in 2021, then dropped by -14bps to 16.59% in 2022, then skyrocketed by 36bps to 22.6% in 2023, then increased by 19bps to 26.84% in 2024, then surged by 1527bps to 436.71% in 2025.
  • Its EBITDA Margin stands at 436.71% for Q4 2025, versus 616.58% for Q3 2025 and 454.15% for Q2 2025.